The Rosen Law Firm has announced an ongoing securities class action against REGENXBIO, Inc., alleging the company made materially misleading statements regarding its RGX-111 gene therapy program. According to the litigation, REGENXBIO failed to adequately disclose adverse efficacy and safety data related to the therapeutic candidate, potentially affecting investor decisions during the relevant holding period.
Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026 may qualify as class members in the action. The firm is encouraging eligible shareholders to consult with legal counsel regarding their potential claims and participation rights.
The deadline to serve as lead plaintiff in the case is April 14, 2026. Lead plaintiffs play a significant role in class action proceedings, working with counsel to represent the broader class of affected investors. Interested parties are advised to contact legal counsel promptly to ensure compliance with all procedural requirements and deadlines associated with the litigation.